---
title: "Heterogeneity in Excess Mortality by Diagnosis, Care Setting, and Substance Use in Finland Cohort"
id: "medrxiv-17-heterogeneity-in-excess-mortality-across-mental-behavioural-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-heterogeneity-in-excess-mortality-across-mental-behavioural-and"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.02.26362001v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Heterogeneity in Excess Mortality by Diagnosis, Care Setting, and Substance Use in Finland Cohort
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-heterogeneity-in-excess-mortality-across-mental-behavioural-and
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.02.26362001v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Nationwide Finnish cohort (5,526,599 residents aged 5–95) followed from 2011–01–01 to 2023–12–31 examined **excess mortality** associated with mental, behavioural, and neurodevelopmental disorders using primary and specialist care and population registers. - At cohort entry individuals had no recorded prevalent mental disorder; during follow-up 1,463,064 (26.5%) received a mental disorder diagnosis. - Outcomes included all-cause mortality, mortality rate ratios (**MRRs**), and 10-year differences in restricted mean survival time (**RMST**). - Excess mortality varied substantially by **diagnosis**, psychiatric **care setting**, presence of **substance use disorder (SUD)**, and time since first diagnosis. - Among people aged 5–64 with any mental disorder, adjusted MRRs across care setting and SUD strata ranged from 1.54 (95% CI, 1.39–1.71) to 8.97 (7.86–10.24). - MRRs were highest immediately after first diagnosis and declined over the first 2–3 years of follow-up. - At 3 years after diagnosis, MRRs for depressive, anxiety or fear-related, and stress-related disorders in individuals without SUD treated outside specialist psychiatric care ranged from 0.88 (0.79–0.98) to 1.20 (1.12–1.29) in men and 0.81 (0.73–0.89) to 1.13 (1.04–1.22) in women. - MRRs for schizophrenia and other primary psychotic disorders at 3 years remained elevated: 1.84 (1.60–2.12) in men and 1.55 (1.37–1.75) in women. - Ten-year survival loss across all mental disorders equaled 0.53 years (95% CI, 0.53–0.54) in men and 0.34 years (0.33–0.34) in women, with greater loss for natural versus external causes. - Authors conclude that estimates from specialist psychiatric populations or averages across follow-up can misrepresent mortality in the broader diagnosed population; heterogeneity by diagnosis, context, and time since diagnosis is important. - Data access is restricted and requires authorization from Finnish authorities; the study had ethical approval from the Finnish Institute for Health and Welfare IRB and data linkage authorized by Statistics Finland and THL.
## Clinical Analysis & Structured Key Points
Heterogeneity in Excess Mortality Across Mental, Behavioural, and Neurodevelopmental Disorders | medRxiv Skip to main content Heterogeneity in Excess Mortality Across Mental, Behavioural, and Neurodevelopmental Disorders View ORCID Profile Kimmo Suokas , Mai Gutvilig , Kaisla Komulainen , Jussi Alho , View ORCID Profile John J McGrath , Sami Pirkola , Sonja Lumme , Marko Elovainio , View ORCID Profile Christian Hakulinen doi: https://doi.org/10.64898/2026.09.02.26362001 Kimmo Suokas 1 University of Helsinki; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kimmo Suokas For correspondence: kimmo.suokas{at}helsinki.fi Mai Gutvilig 1 University of Helsinki; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kaisla Komulainen 1 University of Helsinki; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jussi Alho 1 University of Helsinki; Find this author on Google Scholar Find this author on PubMed Search for this author on this site John J McGrath 2 The University of Queensland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for John J McGrath Sami Pirkola 3 University of Tampere; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sonja Lumme 4 Finnish Institute for Health and Welfare Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marko Elovainio 1 University of Helsinki; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christian Hakulinen 1 University of Helsinki; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Christian Hakulinen Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Importance: Excess mortality associated with mental disorders is well established, but estimates are largely based on specialist psychiatric populations. Whether they characterize mortality in the broader diagnosed population is uncertain. Objective: To characterize heterogeneity in excess mortality by diagnosis, psychiatric care setting, substance use disorder (SUD), and time since diagnosis. Design: Nationwide population-based cohort study with follow-up from January 1, 2011, through December 31, 2023. Setting: Primary and specialist health care and population registers in Finland. Participants: Residents aged 5 to 95 years without a recorded prevalent mental disorder at cohort entry. Exposures: Mental, behavioural, and neurodevelopmental disorders classified using ICD-11, with time-varying psychiatric care setting and SUD status. Main Outcomes and Measures: All-cause mortality, mortality rate ratios (MRRs), and 10-year differences in restricted mean survival time (RMST). Results: Among 5,526,599 individuals (2,784,897 [50.4%] women), 1,463,064 (26.5%) received a mental disorder diagnosis. Excess mortality varied substantially by diagnosis, clinical subgroup, and time since diagnosis. Among those aged 5 to 64 years with any mental disorder, adjusted MRRs across care setting and SUD strata ranged from 1.54 (95% CI, 1.39-1.71) to 8.97 (7.86-10.24). MRRs were highest immediately after first diagnosis and declined during the first 2 to 3 years. At 3 years, MRRs for depressive, anxiety or fear-related, and stress-related disorders among individuals without SUD treated outside specialist psychiatric care ranged from 0.88 (0.79-0.98) to 1.20 (1.12-1.29) in men and from 0.81 (0.73-0.89) to 1.13 (1.04-1.22) in women, whereas MRRs for schizophrenia and other primary psychotic disorders remained 1.84 (1.60-2.12) in men and 1.55 (1.37-1.75) in women. Ten-year survival loss across all mental disorders was 0.53 years (95% CI, 0.53-0.54) in men and 0.34 years (0.33-0.34) in women and was greater for natural than external causes. Conclusions and Relevance: Excess mortality varied markedly by diagnosis, clinical context, and time since diagnosis and was small in some common disorders outside specialist psychiatric care without SUD. Estimates derived from specialist psychiatric populations or averaged across follow-up may therefore provide an incomplete picture of mortality in the broader diagnosed population. Competing Interest Statement KS reports lecture fees from Lundbeck, outside the submitted work. All other authors declare no competing interests. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study received favorable ethical review from the Finnish Institute for Health and Welfare (THL) Institutional Review Board, and data linkage was authorized by Statistics Finland and THL. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data used in this study are maintained by Statistics Finland and the Finnish Institute for Health and Welfare (THL), which act as data controllers for the respective datasets. Access to the data is subject to restrictions and requires authorization from the relevant authorities. For more information, see www.findata.fi and www.stat.fi. Funder Information Declared Finnish Medical Association, https://ror.org/04xfxym47 , 9198 European Research Council , 101040247 Research Council of Finland , 354237 , 374509 , 370659 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 04, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Heterogeneity in Excess Mortality Across Mental, Behavioural, and Neurodevelopmental Disorders Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Heterogeneity in Excess Mortality Across Mental, Behavioural, and Neurodevelopmental Disorders Kimmo Suokas , Mai Gutvilig , Kaisla Komulainen , Jussi Alho , John J McGrath , Sami Pirkola , Sonja Lumme , Marko Elovainio , Christian Hakulinen medRxiv 2026.09.02.26362001; doi: https://doi.org/10.64898/2026.09.02.26362001 Share This Article: Copy Citation Tools Heterogeneity in Excess Mortality Across Mental, Behavioural, and Neurodevelopmental Disorders Kimmo Suokas , Mai Gutvilig , Kaisla Komulainen , Jussi Alho , John J McGrath , Sami Pirkola , Sonja Lumme , Marko Elovainio , Christian Hakulinen medRxiv 2026.09.02.26362001; doi: https://doi.org/10.64898/2026.09.02.26362001 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (615) Allergy and Immunology (896) Anesthesia (327) Cardiovascular Medicine (4777) Dentistry and Oral Medicine (476) Dermatology (410) Emergency Medicine (645) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1617) Epidemiology (15853) Forensic Medicine (32) Gastroenterology (1196) Genetic and Genomic Medicine (6996) Geriatric Medicine (727) Health Economics (1059) Health Informatics (4999) Health Policy (1428) Health Systems and Quality Improvement (1742) Hematology (583) HIV/AIDS (1338) Infectious Diseases (except HIV/AIDS) (16251) Intensive Care and Critical Care Medicine (1163) Medical Education (665) Medical Ethics (151) Nephrology (721) Neurology (7208) Nursing (365) Nutrition (1074) Obstetrics and Gynecology (1233) Occupational and Environmental Health (1002) Oncology (3581) Ophthalmology (1039) Orthopedics (394) Otolaryngology (448) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1782) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5846) Public and Global Health (9705) Radiology and Imaging (2392) Rehabilitation Medicine and Physical Therapy (1436) Respiratory Medicine (1245) Rheumatology (635) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (769) Toxicology (107) Transplantation (303) Urology (287)
## Related Clinical Research

- [Prevalence, Severity and Predictors of Antipsychotic-Related Adverse Drug Reactions in a Ugandan R](https://medichelpline.com/clinical-feed/plos-one-14-prevalence-severity-and-predictors-of-antipsychotic-related-adverse-drug.md)
- [Lithium in Pregnancy: Risks of Preterm Birth, LGA, and Cardiac Malformations](https://medichelpline.com/clinical-feed/womens-mental-health-0-lithium-use-in-pregnancy-and-the-risk-of-adverse-perinatal-outcomes.md)
- [Polygenic and familial influences on antidepressant continuation, switching, discontinuation and a](https://medichelpline.com/clinical-feed/medrxiv-13-polygenic-and-familial-contributions-to-antidepressant-continuation-switching.md)
- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)
- [Pregabalin for Treatment-Resistant Generalised Anxiety Disorder: Statistical Analysis Plan for the](https://medichelpline.com/clinical-feed/medrxiv-16-pregabalin-for-treatment-resistant-generalised-anxiety-disorder-statistical.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.